Pharmaceuticals

Sanyou's STAL helps researchers to explore the forefront of Life Sciences with high-impact literature publication

SHANGHAI, June 7, 2023 /PRNewswire/ -- Since the establishment of Super-Trillion Innovative Antibody Library (STAL), Sanyou has collaborated with or assisted scientists in publishing dozens of articles, of which 41 have a cumulative impact factor of 412.32, 14 papers have an impact factor greater...

2023-06-07 20:00 2721

ACROBiosystems expands custom GMP-grade protein services to drive CGT development and commercialization

NEWARK, Del., June 7, 2023 /PRNewswire/ -- Cell and gene therapy (CGT) is a cutting-edge therapy that combats cancer by bolstering the immune system through stem cell infusions or modified immune cells. However, manufacturing cell therapies is no easy feat. Cell therapy products have a higher R&D...

2023-06-07 14:57 3109

ImmVira presented latest encouraging clinical results of two proprietary products at ASCO 2023

SHENZHEN, China, June 6, 2023 /PRNewswire/ -- ImmVira submitted four abstracts covering latest results from Phase I/II clinical trials of MVR-T3011 IT (intratumoral injection) and MVR-T3011 IV (intravenous injection) in both U.S. andChina with all selected to be published (1 chosen for poster dis...

2023-06-07 08:00 2898

Fosun Pharma Participates in 2023 BIO International Convention to Demonstrate its Global Innovation Capabilities

BOSTON, June 6, 2023 /PRNewswire/ -- From June 5th to 8th (Pacific Standard Time), the 2023 BIO International Convention ("BIO 2023") will be held in Boston, Massachusetts, USA. The BIO International Convention is the world's largest gathering of the biotechnology industry along with industry-lead...

2023-06-06 22:15 4028

Fosun Pharma and IFC Partner to Improve Access to High Quality Medicines in Africa

ABIDJAN, Côte d'Ivoire, June 6, 2023 /PRNewswire/ -- To support stronger healthcare delivery and outcomes inWest Africa, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma or the Company, stock code: 600196.SH; 02196.HK) today announced a deepening partnership with IFC to help the comp...

2023-06-06 19:52 3470

2023 ASCO | Multi-center Data for Combination Study of GenFleet's GFH018 (TGF-β R1 inhibitor) with Anti-PD-1 Antibody Demonstrates Significant Potential to Enhance Efficacy of Immune Checkpoint Inhibitors among ICI-naïve Patients

SHANGHAI and CHICAGO, June 6, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today published the latest results from the phase Ib/II study of GFH018 (TGF-β R1 inhibitor) with toripalimab(anti-PD-1 ...

2023-06-06 19:00 2378

Samsung Biologics accelerates timeline of new fifth plant to be operational by April 2025

- Marking the first phase of the company's second Bio Campus, Plant 5 is expected to have shortest construction timeline - Samsung Biologics will maintain the world's largest biomanufacturing capacity at 784,000 liters upon completion of the newest plant - Key features of Plant 5 include seamless ...

2023-06-06 19:00 2837

Live from ASCO 2023 | Ascentage Pharma Releases Updated Data Showing APG-2449's Potential as a New Treatment for Drug-Resistant NSCLC

SUZHOU, China and ROCKVILLE, Md., June 6, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that for the second consecutive year, it has release...

2023-06-06 12:20 3791

Live from ASCO 2023 | Ascentage Pharma Releases the First Dataset of Lisaftoclax in WM, Revealing Encouraging Therapeutic Potential

SUZHOU, China and ROCKVILLE, Md,, June 5, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released preliminary results from a Phas...

2023-06-06 10:45 2665

Cali Biosciences Initiates Second Phase III Study of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use and Presents Consistent and Predictable PK Results Across Multiple Surgeries

* Subjects in Bunionectomy Study Dosed  * Data Presented at American Society for Pharmacology and Experimental Therapeutics Shows Similar Ropivacaine Pharmacokinetic Curves From CPL-01 Across Multiple Surgeries; Minimal Variability as Compared to Liposomal Bupivacaine SAN DIEGO, June 5, 2023 ...

2023-06-06 00:00 3168

Russellville Hospital and United Imaging Announce First Installation in the U.S. of the 4 cm uCT(R) ATLAS Computed Tomography Scanner

Russellville Hospital Moved Quickly To Bring High-End Technology to Patients HOUSTON, June 5, 2023 /PRNewswire/ -- United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, confirmed that Russellville Hospital is the first customer to complete installat...

2023-06-05 22:00 2556

Live from ASCO 2023 | For the Third Consecutive Year, Ascentage Pharma Releases Promising Results of Alrizomadlin plus Pembrolizumab in Patients with Cutaneous Melanoma that Failed Immuno-Oncologic (IO) Therapies

SUZHOU, China, and ROCKVILLE, Md., June 5, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated results from a Phase I...

2023-06-05 17:34 2766

Lunit and Capio S:t Göran Hospital Collaborate to Address Radiologist Shortage with AI-Powered Mammography Analysis

- Lunit and Sweden's largest private hospital pioneering a new approach to combine radiologists' expertise with AI SEOUL, South Korea, June 5, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading global provider of AI-powered cancer diagnostic solutions, today announced the signing of a supply ...

2023-06-05 15:00 2572

Gencurix Announces Clinical Research Results At ASCO 2023 Demonstrating Outstanding Performance of GenesWell BCT, the Company's Breast Cancer Prognostic Test, Compared to Global Best-Selling Test, OncotypeDX

SEOUL, South Korea, June 4, 2023 /PRNewswire/ -- Gencurix (KOSDAQ #229000), a leading provider of cancer molecular diagnostics, announced the release of clinical research results directly comparing the accuracy of its breast cancer prognostic test, GenesW...

2023-06-05 14:37 3361

American Society of Clinical Oncology confers highest honor upon Prof Hagop Kantarjian

SUZHOU, China and ROCKVILLE, Md., June 5, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its Clinical Advisory Board member ProfHago...

2023-06-05 12:30 2390

Live from ASCO 2023 | Updated Data of Olverembatinib in SDH-Deficient GIST including a CBR of 93.8% Signals a Potential Clinical Breakthrough

SUZHOU, China and ROCKVILLE, Md., June 4, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated clinical results of olv...

2023-06-05 11:51 2609

Harbour BioMed Announces First Patient Dosed in Phase I Study of First-in-Class Anti-B7H7 (HHLA2) Antibody HBM1020

* HBM1020 is a first-in-class therapeutic monoclonal antibody against B7H7/HHLA2 entering clinical development globally. * HBM1020 was generated from Harbour Mice® H2L2 transgenic mice platform. * HBM1020 has great potential to address huge unmet medical needs in patients with advanced malig...

2023-06-05 09:01 2630

VVN539 met primary study endpoints in US phase IIa clinical study for the treatment of glaucoma

SHANGHAI, June 4, 2023 /PRNewswire/ -- This was a Phase 2, double-masked, randomized, vehicle-controlled, dose-response study to assess the safety and ocular hypotensive efficacy of VVN539 in subjects with primary open angle glaucoma (POAG) or ocular hypertension (OHT). The primary objective was ...

2023-06-05 08:00 2553

Sanyou launches new European offices and continues to promote global business landscape

SHANGHAI, June 3, 2023 /PRNewswire/ -- In May 2023, following the CIC Boston branch in US, Sanyou opens new offices in The Shard London and CIC Rotterdam respectively, to rapidly promote the globalization of business landscape. Headquartered in Shanghai China, Sanyou Biopharmaceuticals Co., Ltd. ...

2023-06-03 20:05 3837

TWi Biotechnology Exploring Promising Treatment for Granuloma Annulare (GA)

Company and Yale University Hospital seeking participants with GA for Phase 1 trials of medicine FDA-approved for other ailments NEW HAVEN, Conn., June 2, 2023 /PRNewswire/ -- TWi Biotechnology (TWiB), a clinical stage biopharmaceutical company specializing in development of repositioned drugs f...

2023-06-02 15:51 2281
1 ... 87888990919293 ... 153

Week's Top Stories